{"id":"placebo-for-bexagliflozin","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1808388","moleculeType":"Small molecule","molecularWeight":"464.94"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action. It is used as a control in clinical trials to compare the efficacy of active treatments.","oneSentence":"Placebo does not have a known mechanism of action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:55.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05612594","phase":"PHASE4","title":"Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-03-27","conditions":"Sleep Apnea","enrollment":164},{"nctId":"NCT03514641","phase":"PHASE2, PHASE3","title":"An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-18","conditions":"Essential Hypertension","enrollment":673},{"nctId":"NCT02558296","phase":"PHASE3","title":"Bexagliflozin Efficacy and Safety Trial","status":"COMPLETED","sponsor":"Theracos","startDate":"2015-10","conditions":"Type 2 Diabetes Mellitus","enrollment":1700},{"nctId":"NCT03259789","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-11-28","conditions":"Type2 Diabetes Mellitus","enrollment":351},{"nctId":"NCT02836873","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-09-23","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT02390050","phase":"PHASE2","title":"A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Theracos","startDate":"2015-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":292},{"nctId":"NCT02715258","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-03","conditions":"Type 2 Diabetes Mellitus","enrollment":210},{"nctId":"NCT03115112","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-12","conditions":"Type 2 Diabetes Mellitus","enrollment":386},{"nctId":"NCT02769481","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-08-15","conditions":"Type 2 Diabetes Mellitus","enrollment":426}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Bexagliflozin","genericName":"Placebo for Bexagliflozin","companyName":"Theracos","companyId":"theracos","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo does not have a known mechanism of action. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}